Barzilai University Medical Center

86 Research Day 2020 Barzilai University Medical Center 61 THE USE OF BONE MARROW ASPIRATE CONCENTRATE (BMAC) AND DEMINERALIZED BONE MARROW ASPIRATE (DBM) IN UNICAMERAL BONE CYST PATIENT. Ortal Segal 1 , Ron Batash 2 , Solomon Dadia 1 , Amir Sterenheim 1 , Yehuda Kollender 1 , Yair Gorchak 1 1 Orthopedic Oncology unit, Tel Aviv Medical Center, Tel Aviv Israel. 2 Department of Orthopedics, Barzilai University Medical Center, Ashkelon, Israel Background Unicameral bone cysts (UBC) are benign lesions, which may grow with time and thin the involved bone. The proximal humerus bone account for almost 80% of the cases. The treatment is continuously evolving, e.g. intralesional injection, decompression and combined surgical techniques Hypothesis After receiving the approval of the local ethics committee, the history records of 30 consecutive patients mean age 11 years of age (range 9-17 years), treated with BMAC+DBM intra-lesional injections, were analyzed. Patient follow-up was average 2.8 years (range 1.3-3 years) after injections. All patients had following X-ray images and functional assessments. Objectives To demonstrate the results of intra-lesional injection using Bone Marrow Aspirate Concentrate (BMAC) and Demineralized Bone Marrow Aspirate (DBM). Results Out of 30 patients 14 patients required a second injection due to relapse of the lesion. 8 of the 14 patients required a third injection. 4 patients were referred to a surgery with Allograft chips. A re- fracture was seen in average 2 years (range 1.9-3) from the injection in 4 patients. Conclusions The use of BMAC+DBM in UBC lesion can be an efficient treatment modality. We recommend further research, composing larger study groups versus a control group with longer follow up periods.